GlassScriptPhysician profile
Ahmad Bilal
NPI 1487747424
$5,753.99
in general payments reported to CMS, 2019-2025
29 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $217 · 2021: $308 · 2022: $509 · 2023: $2,160 · 2024: $974 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,299.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,080.83 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Abbvie INC. | $640.90 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $620.42 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $495.15 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Alkermes, INC. | $494.21 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $410.57 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $291.12 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Corium, LLC | $284.01 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $148.66 | 2022-2025 | Trintellix |
| Almatica Pharma LLC | $130.89 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $128.03 | 2023-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $103.44 | 2024-2025 | Cobenfy |
| Indivior INC. | $103.01 | 2023-2024 | Perseris |
| Lundbeck LLC | $98.12 | 2023-2025 | Rexulti |
| Tris Pharma INC | $92.51 | 2022-2025 | Dyanavel Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $81.72 | 2024 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $75.57 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $73.66 | 2023-2024 | Quviviq |
| Bioxcel Therapeutics, INC. | $57.66 | 2023 | Igalmi |
| Avanir Pharmaceuticals, INC. | $56.49 | 2022 | |
| Supernus Pharmaceuticals, INC. | $45.92 | 2024-2025 | Qelbree |
| Allergan, INC. | $35.59 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $34.41 | 2025 | Fanapt |
| Neuronetics, INC. | $33.38 | 2023-2024 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $32.61 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $32.58 | 2023 | Methylphenidate Hydrochloride |
| Sunovion Pharmaceuticals INC. | $29.57 | 2020 | |
| Sage Therapeutics, LLC | $23.84 | 2023 | |
| Neos Therapeutics, LP | $19.12 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Bilal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.